Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ID: DRG0SACUI)
| ADC Name |
BB-1705
|
|||||
|---|---|---|---|---|---|---|
| Synonyms |
BB-1705
Click to Show/Hide
|
|||||
| Organization |
Bliss Biopharmaceutical (BlissBio) (Originator);Morphotek
|
|||||
| Drug Status |
Phase 1/2
|
|||||
| Drug-to-Antibody Ratio |
2
|
|||||
| Structure |
|
|||||
| Antibody Name |
Anti-EGFR antibody
|
Antibody Info | ||||
| Antigen Name |
Epidermal growth factor receptor (EGFR)
|
Antigen Info | ||||
| Payload Name |
Eribulin
|
Payload Info | ||||
| Payload Target |
Microtubule (MT)
|
Target Info | ||||
| Linker Name |
Mal-PEG2-Val-Cit-PABC
|
Linker Info | ||||
| Conjugate Type |
Random Cysteines
|
|||||
| Combination Type |
ecteribulin
|
|||||
2027 Update
The disease landscape of This ADC
2027 Update
The clinical trial pipelines of This ADC
General Information of The Activity Data Related to This ADC
Identified from the Human Clinical Data
Full List of Activity Data of This Antibody-drug Conjugate
Identified from the Human Clinical Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Patients Enrolled |
Eligible patients are adults (≥18 years) with histologically confirmed advanced/metastatic solid tumors (RECIST 1.1 measurable lesions), ECOG 0-1, and adequate organ function. Key exclusions include recent anticancer therapy, uncontrolled CNS metastases, ≥Grade 2 peripheral neuropathy, active pneumonitis/ILD, or significant comorbidities (e.g., QTc prolongation). Contraception is required during treatment and for 6 months post-dose.
Click to Show/Hide
|
||||
| Administration Dosage |
BB-1705 will be administered as an intravenous infusion by Q3W for 8cycles
|
||||
| Related Clinical Trial | |||||
| NCT Number | NCT05217693 | Clinical Status | PHASE1 | ||
| Clinical Description | A Phase I First-in-human, Open Label, Multicenter, Dose Escalation and Cohort Expansion Study to Investigate the Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of BB-1705 in Patients With Locally Advanced/Metastatic Solid Tumors | ||||
| Primary Endpoint |
The study evaluates safety by monitoring adverse events (AEs) and serious adverse events (SAEs) for up to 2 years, with dose-limiting toxicities (DLTs) assessed during Cycle 1 (21 days) to determine the maximum tolerated dose (MTD) based on NCI-CTCAE criteria.
|
||||
| Other Endpoint |
Pharmacokinetic analysis includes AUC0-inf and Cmax measurements during Cycles 1-8 (21-day cycles), while immunogenicity is assessed via anti-drug antibodies (ADAs). Efficacy endpoints include objective response rate (ORR), progression-free survival (PFS), and duration of response (DOR) evaluated every 6-9 weeks for up to 2 years.
|
||||
| Experiment 2 Reporting the Activity Date of This ADC | [2] | ||||
| Related Clinical Trial | |||||
| NCT Number | NCT05217693 | Clinical Status | Phase 1/2 | ||
| Clinical Description | A phase 1/2 first-in-human, open label, multicenter, dose escalation and cohort expansion study to investigate the safety, tolerability, pharmacokinetics and preliminary antitumor activity of BB-1705 in patients with locally advanced/metastatic solid tumors. | ||||
References